Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

modified vaccinia Ankara (Bavarian Nordic)-HER2 vaccine

A cancer vaccine consisting of a proprietary, recombinant modified vaccinia Ankara (MVA) viral vector encoding an epitope of human epidermal growth factor receptor 2 (HER2) with potential antineoplastic activity. Upon administration, modified vaccinia Ankara (Bavarian Nordic)-HER2 vaccine may stimulate the host immune system to mount humoral and cytotoxic T lymphocyte responses against HER2-expressing tumor cells, resulting in tumor cell lysis. HER2, also known as ErbB-2, is a tyrosine kinase growth factor receptor and a member of the epidermal growth factor receptor family; it plays a significant role in the pathogenesis of some breast cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:MVA-BN-HER2 vaccine
Foreign brand name:MVA-BN Breast
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search